Topics

Gilead gets 2nd HIV drug approved for PrEP, but its own Truvada may be hard to dethrone

16:46 EDT 4 Oct 2019 | MedCity News

Although Descovy showed an advantageous side-effect profile, one doctor described Truvada as mostly well-tolerated, while another said switching to Descovy will depend on insurance coverage. Both expressed a desire for data in other vulnerable populations.

Original Article: Gilead gets 2nd HIV drug approved for PrEP, but its own Truvada may be hard to dethrone

NEXT ARTICLE

More From BioPortfolio on "Gilead gets 2nd HIV drug approved for PrEP, but its own Truvada may be hard to dethrone"

Quick Search